Breaking away from tradition is the aim of the game for Curemark, with the company’s novel therapies intended to make their mark on the world of neurological conditions where they can address underserved and medically necessary conditions for which there is no or very little treatment. Following the pathway of disruptive technology, this is a firm that ploughs its own furrow and leads the way for the industry at large. In the light of their award-winning success, we turn to this hardworking team to find out more.
The work that Curemark does is not unique, but the way in which it goes about it is thoroughly inimitable. Motivated by the desire to understand the needs and desires of patients and their families, Curemark’s approach is marked by a kindness and individual nature that is not often seen in biopharmaceutical companies.
The vision behind Curemark is one of reinvention, with no aspect of the development process taken for granted. Traditionally, candidates for drugs are developed in a laboratory setting, with scientific insights feeding into the molecular biology and physiology of the disease. It is from these insights that drugs are further developed, and only during the clinical testing phase is the experience of the patient relevant.
The Curemark approach places the patient front and center. It is how the company first began. Led by the work of Founder and CEO Dr. Joan Fallon, who’s Autism research into children began in the clinic, the team were able to make remarkable discoveries directly from the patients. This was fed into new ideas and developments. During her work with children, she identified a common enzyme deficiency which led to the development of CM-AT.
With up to 1 in 68 children diagnosed with Autism, and an overall 1% of the population, the desire for a drug that treats the core symptoms is something that is often searched for. CM-AT was the figurehead for a new way of working and is currently the lead drug candidate for the company. Referred to as the BlümTM Study, it has progressed to a Phase III clinical trial for Autism amongst 3-8 year olds. The FDA has awarded the study “Fast Track” designation, with a rolling review of its New Drug Application for CM-AT.
This recognition at a Federal level shows not only the way in which Curemark is responding to a clear need in the population, but also the seriousness with which the FDA have taken the need as well. The pipeline for potential drugs candidates currently includes a mix of clinical-stage and preclinical
programs, each aimed at challenging areas for clinicians, including ADHD, Parkinson’s, schizophrenia and addiction.
Much of this work is based on the role of amino acids in neurological diseases. Amino acids play a significant role in several of the body’s major functions, including protein synthesis, CNS gene regulation and the formation of key neurotransmitters, such as serotonin and dopamine. Enzymatic deficiencies, such as the one identified in Autism, may play a key role in the etiology of diseases such as Parkinson’s. In this case, the newly developed CM-PK may be able to affect dopamine levels in PD patients while also improving postural instability and reducing falls.
The team at Curemark has garnered the support of some of the finest minds in the industry, drawing together a unique tapestry of experience. This means that at every level, from medical to operational, the company is guided by formidable expertise that counters the brave new approaches put forward.
Curemark has pushed forward a new way of thinking in the biopharmaceutical industry, trying different ways to address the needs of their patients. It’s because of this innovative approach that it has grown into such an incredible success.
Contact: Jason Friedman